Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsP2Y12 platelet receptors: importance in percutaneous coronary interventionInterplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis.Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational studyThe Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count.Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.Percutaneous coronary intervention in nonagenarians: pros and cons.Advances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic strokeNew antiplatelet agents for cardiovascular disease.Bleeding events and maintenance dose of prasugrel: BLESS pilot study.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary SyndromesShould platelet function testing guide antiplatelet therapy for patients with coronary artery stenting or acute coronary syndromes?Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease.Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.Assessing post-treatment platelet reactivity: a focus on patient selection and setting.Dual antiplatelet therapy dilemmas: duration and choice of antiplatelets in acute coronary syndromes.Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account.New antithrombotics for secondary prevention of acute coronary syndrome.Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease.Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.Resistance to antiplatelet drugs: what progress has been made?Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes.Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention.Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy.Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes.Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.Duration of dual antiplatelet therapy in acute coronary syndromeAdvocating cardiovascular precision medicine with P2Y12 receptor inhibitors.The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease?Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity.P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activationDual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
P2860
Q26775125-8CF3323F-AEE1-4F5F-8ACF-40D456228163Q33655109-86F71C3B-128C-41A5-A99C-F07609955833Q33933475-3414D023-B456-4F1F-BCC1-1601E85EE2CAQ33963651-BF93B731-C337-4B55-BF78-DAB4F8E72DE5Q34763870-46147FDC-62B5-4048-BF75-CAA8F549780CQ35204942-C4CFA68E-4A66-4497-B4A7-19304EBAFC31Q35208684-4319D600-500C-4C48-BC58-E66A15F6BE29Q35677083-F003F22A-7F6E-4116-AE9E-B8A2C92A1309Q35925903-9415C1FA-748F-433F-9A3B-12E4AA7BD553Q36216424-4DB819A7-81FA-484E-98FE-A254B424F922Q36769847-5FC27DFE-F1B6-4EAC-A0DF-02B18511E931Q37051838-9097109C-5AE9-41A1-AC34-E2AB6708D379Q37304566-17C4836D-6E72-4751-B917-34F16B3AD688Q37390051-F1F9EC82-A5B2-44AE-909C-5B4EEDF733FFQ37497555-29823303-50F5-4185-ADBC-7A7E644C9190Q37556037-E9049D43-EF9A-4FCF-8DA4-7EC07E073387Q37588812-17F21BA0-9777-4C12-8DEB-373B224CAABEQ38071262-8EC4F159-3B48-4FDB-B479-E72E391D63ACQ38130753-A69C47FA-2EAA-44A5-8AD4-784983DBE375Q38132252-06BFFCF9-522D-496D-A1B0-8451055C93B1Q38132923-E55F728B-D8E7-413B-9D68-FD5F9EC25118Q38137724-D3A9CFAE-885C-41F6-9FE6-773E7BEC34F8Q38154612-897B8F9D-F6D8-49C8-8C5D-8A6A49353C62Q38180991-610124EF-4B21-47E6-8F82-6A56E4EE44F8Q38182003-72D594CD-08CF-49A7-B74B-F9AD62B2DA3DQ38216499-192968E4-906D-4688-BEFF-0A29396CD227Q38258270-D9F85DB2-1930-4586-8888-1C944C3E5AF8Q38262149-E63DB350-3ACB-46A6-8360-C87AF38F29EDQ38340126-05E6E929-7030-4606-8272-B1E5ED7F994FQ38366950-5223D17D-3188-4FD8-881F-5F6DD164D68FQ38378213-7A4752A6-AD6A-4E6F-B099-535A682DF1D7Q38444425-475B9409-0C56-43EC-9D0E-51D1DB360721Q38751834-4C951220-A31E-4F75-96D5-3705E30EEB90Q38958862-218C299B-A001-460F-A980-8CD2EFF94E76Q39010701-FC3AEABF-EEB3-462D-ACBE-F7A0E3EF8AC8Q39025194-76FCEF5C-E40F-4879-A672-0C2482E25048Q39187857-E2D83DA2-4C54-4335-BBA6-96070A4576DCQ39221284-A70818BD-560F-4B7C-8F45-F9A4C5967B3DQ39550267-86D0103C-1F04-42FE-9AC5-FD46B44456F7Q40031080-3FE7AAAC-29EE-4B89-A1F3-D43D8089BFF0
P2860
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Platelet function during exten ...... CS platelet function substudy.
@en
type
label
Platelet function during exten ...... CS platelet function substudy.
@en
prefLabel
Platelet function during exten ...... CS platelet function substudy.
@en
P2093
P50
P356
P1476
Platelet function during exten ...... CS platelet function substudy.
@en
P2093
Benjamin Neely
Chunmei Zhou
David Erlinge
Eileen Brown
Harvey D White
Jan H Cornel
Joseph A Jakubowski
Keith A A Fox
Kurt Huber
Mark Y Chan
P304
P356
10.1001/JAMA.2012.17312
P407
P577
2012-11-01T00:00:00Z